Test Price
2,800 AED✅ Home Collection Available
LRSAM1 Gene CMT2P Genetic Test in UAE | 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
99.9% Diagnostic Sensitivity via ISO Certified Processing
Next‑generation sequencing with Sanger confirmation, performed in a facility holding ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139).
Premium Hospital‑Grade Home Collection
VIP mobile phlebotomy and temperature‑controlled cold‑chain logistics, available daily from 8 AM to 11 PM.
Telephonic Post‑Test Clinical Guidance
Expert interpretation of results by a Consultant Medical Geneticist, correlating genotype with personal and family history.
Direct Insurance Billing Verification
Quick confirmation via WhatsApp +971 54 548 8731, compliant with Federal Decree‑Law No. 45 of 2021 (PDPL).
Test Overview & Methodology
The LRSAM1 Gene CMT2P Genetic Test is a targeted next‑generation sequencing assay that identifies pathogenic mutations in the LRSAM1 gene responsible for Charcot‑Marie‑Tooth disease type 2P (CMT2P). This high‑precision diagnostic confirms the molecular basis of hereditary motor‑sensory neuropathy, enabling personalised treatment plans and family screening in the UAE. Illumina‑based NGS with minimum 100× mean coverage is used, and all clinically significant findings are validated by Sanger sequencing to ensure 99.9% analytic sensitivity.
| Feature | Our Test (LRSAM1 CMT2P NGS) | Closest Alternative (Single‑Gene Sanger) |
|---|---|---|
| Diagnostic Precision | 99.9% sensitivity, deep coverage and Sanger validation | ~95% sensitivity, may miss large deletions or duplications |
| Methodology | Illumina‑based NGS plus confirmatory Sanger | PCR followed by Sanger sequencing only |
| Turnaround Time | 3–4 weeks (expedited on request) | 6–8 weeks typical for custom single‑gene assays |
| Clinical Utility | Covered by top UAE insurance; DHA‑compliant | Often not reimbursed for targeted CMT2P alone |
Physician Insight & Safety Protocols
“In my practice across UAE genetics clinics, I have observed that a definitive LRSAM1 result can significantly alter clinical management. A positive mutation confirms CMT2P, but it does not predict the individual rate of progression; results must always be correlated with nerve conduction studies and a comprehensive three‑generation pedigree. Please review your results with your neurologist before adjusting any therapy.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Clinical Advisory
Important Safety Information
⚠️ Do not discontinue prescribed medication without consulting your doctor. This genetic test is an aid to diagnosis; it does not replace serial neurological evaluation or clinical judgment. Always interpret results within the full context of physical examination and family history.
Exclusion Criteria & Emergency Red Flags
Contraindications and Urgent Warnings
- Not intended for acute neurological emergencies; results are not available in real‑time.
- Test cannot be performed on clotted, haemolysed, or insufficient DNA samples.
- If you experience sudden weakness, respiratory difficulty, or swallowing problems, seek immediate emergency care.
- Minors require parental or guardian consent and genetic counselling per Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Patient FAQ & Clinical Guidance
1. What is the purpose of the LRSAM1 gene test?
The LRSAM1 CMT2P NGS test detects pathogenic mutations causing Charcot‑Marie‑Tooth disease type 2P, a progressive motor‑sensory neuropathy. It is recommended when clinical findings and family history suggest autosomal dominant CMT2P. A positive result confirms the diagnosis and enables accurate genetic counselling and family risk assessment. The test is suitable for adults and, with appropriate consent, for at‑risk minors under strict UAE paediatric genetic testing regulations.
2. How is the test performed and what is the turnaround time?
Our laboratory requires only a simple blood draw or DNA sample via DHA‑licensed home phlebotomists, with results in 3–4 weeks. You may provide a standard whole blood sample, extracted DNA, or a single drop of blood on an FTA card. Our ISO‑certified cold‑chain logistics preserve sample integrity. The laboratory uses Illumina next‑generation sequencing with mean coverage greater than 100×, and all pathogenic findings are confirmed by Sanger sequencing.
3. Is genetic counselling included?
A pre‑ and post‑ genetic counselling session is mandatory to interpret the pedigree and result implications, ensuring clinical relevance. Our service mandates a structured genetic counselling appointment (in‑clinic or via telehealth) before sample collection. During this session, a certified genetic counsellor constructs a three‑generation pedigree, explains inheritance risks, and obtains informed consent as per UAE PDPL. After results are released, a second counselling session with the ordering clinician connects the genotype to your individual care plan.
UAE Regulatory & Data Privacy Adherence
This laboratory service operates in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data are encrypted during transmission and at rest, with access restricted to authorised clinical personnel only. Patient samples are de‑identified prior to analysis, and results are released exclusively to the ordering physician or the patient through a secure, authenticated portal. Clinical safety and patient consent procedures follow Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | LRSAM1 Gene CMT2P Genetic Test (Next‑Generation Sequencing) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks (Expedite Available on Request) |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or FTA Card Sample |
| Methodology Used | Targeted Next‑Generation Sequencing (Illumina) with Sanger Confirmation |
| ICD-10-CM Code | G60.0 |
| LOINC Code | 94219-8 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians